z-logo
Premium
Identification and assessment of regulatory T cells (Treg*) associated with inflammation and tumorigenesis in Inflammatory Bowel Disease (IBD) patients
Author(s) -
Downey Katherine J,
Wang Yanhua,
Sun Katherine,
Lin Elain,
Wu Yuanyuan,
Liu Qiang
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.645.6
Subject(s) - carcinogenesis , medicine , inflammation , inflammatory bowel disease , cancer , pathogenesis , colorectal cancer , immune system , immunology , disease , ulcerative colitis , regulatory t cell , t cell , il 2 receptor
The pathogenesis of Inflammatory Bowel Disease is multifactorial. A widely accepted theory for the pathogenesis of IBD lays blame on the host's exaggerated immune response to commensal bacteria, implying a loss of self tolerance. Chronic inflammation is a well known risk factor for the development of dysplasia and cancer. Regulatory T cells (Treg*) therefore play a critical role in the regulation of immunity and a pivotal role in tumorigenesis of several cancer types by suppressing anti‐tumor immune responses, thereby promoting tumor progression. We set out to identify and assess Treg* expression in IBD and Cancer patients vs. disease‐free individuals which may help explain tumor progression. Retrospective sequential in‐house cases (n=53): 34 IBD, 9 Colon cancer, and 10 normal. Immunohistochemistry used to delineate Treg* cells. Blinded counts performed using the average of 3 HPF's (40X) in areas of highest concentration. Data analysis by unpaired t‐test and ANOVA reveal significant differences in Treg* expression: IBD >; normal (p<0.001); Cancer >; normal (p<0.001 ); Cancer >; IBD (p<0.003); no significant difference between UC and Crohn's (p=0.371). ANOVA analysis showed statistically significant difference amongst all groups (p<0.001: Cancer >; IBD >; normal). Our results show increased Treg* cells in the cancer arm (cancer >; IBD >;>; normal), thereby supporting an important role of Treg* cells in inflammation and tumorigenesis in IBD. Therapeutic manipulation of Treg* cells (i.e. selective depletion) holds great potential in treating IBD and preventing subsequent tumor progression. Funding provided by Montefiore Medical Center Clinical Research Committee

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here